Iqirvo in Qatar
How patients in Qatar access Iqirvo (resmetirom) via Named Patient Program.
Iqirvo - overview
Iqirvo (resmetirom) is manufactured by Madrigal Pharmaceuticals and indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. It is an oral PPARα/δ dual agonist, 80 mg once daily approved by the US FDA in 2024 and may be accessible to patients in Qatar through a Named Patient Program or personal-import pathway.
Access in Qatar
Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
How Reserve Meds coordinates access in Qatar
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Qatar-specific eligibility.
- Treating physician in Qatar issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Iqirvo from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Qatar.
Typical timeline for Qatar
End-to-end, most requests are completed in 2-6 weeks. Qatar's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Qatar ask
- Is the pathway legal in Qatar? Yes - it operates under Qatar's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Qatar able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.